JP2015521175A - カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位 - Google Patents

カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位 Download PDF

Info

Publication number
JP2015521175A
JP2015521175A JP2015511392A JP2015511392A JP2015521175A JP 2015521175 A JP2015521175 A JP 2015521175A JP 2015511392 A JP2015511392 A JP 2015511392A JP 2015511392 A JP2015511392 A JP 2015511392A JP 2015521175 A JP2015521175 A JP 2015521175A
Authority
JP
Japan
Prior art keywords
granule
fatty acid
dosage unit
granules
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511392A
Other languages
English (en)
Japanese (ja)
Inventor
フリース， ジャン アルバート ド
フリース， ジャン アルバート ド
シド， マリア ヴァネサ フェルナンデス
シド， マリア ヴァネサ フェルナンデス
ロペス， アナ マリア ヘレディア
ロペス， アナ マリア ヘレディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Echo Pharmaceuticals BV
Original Assignee
Echo Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Echo Pharmaceuticals BV filed Critical Echo Pharmaceuticals BV
Publication of JP2015521175A publication Critical patent/JP2015521175A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015511392A 2012-05-07 2013-05-03 カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位 Pending JP2015521175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167006.1 2012-05-07
EP12167006 2012-05-07
PCT/NL2013/050341 WO2013169101A1 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate

Publications (1)

Publication Number Publication Date
JP2015521175A true JP2015521175A (ja) 2015-07-27

Family

ID=48468727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511392A Pending JP2015521175A (ja) 2012-05-07 2013-05-03 カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位

Country Status (9)

Country Link
US (2) US20150132400A1 (enExample)
EP (1) EP2846768B1 (enExample)
JP (1) JP2015521175A (enExample)
CN (1) CN104363890B (enExample)
AU (1) AU2013260246B2 (enExample)
CA (1) CA2872689C (enExample)
ES (1) ES2600465T3 (enExample)
IN (1) IN2014DN09718A (enExample)
WO (1) WO2013169101A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547409A (ja) * 2019-08-30 2022-11-14 サクソー 充填顆粒、これらの製造方法及びこれらの使用
JP2023078465A (ja) * 2014-10-21 2023-06-06 ブラックモン アーネスト ヴィンソン 大麻抽出物ならびにその調製方法および使用方法
JP2023535374A (ja) * 2020-07-17 2023-08-17 カンナ － ケミストリーズ エルエルシー 固体δ９－テトラヒドロカンナビノール（δ９－ｔｈｃ）組成物
JP7360526B1 (ja) 2022-10-21 2023-10-12 第一工業製薬株式会社 組成物
JP2023551415A (ja) * 2020-11-16 2023-12-08 インデナ エッセ ピ ア カンナビジオールの固体分散体
JP7469550B1 (ja) 2022-10-21 2024-04-16 第一工業製薬株式会社 固体組成物及びその製造方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
WO2016205923A1 (en) * 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
CA2914611A1 (en) * 2015-12-09 2017-06-09 Mark Kwiecinski Compositions for improving safety of pharmaceutical formulations
NZ735216A (en) 2016-02-11 2019-08-30 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US10542770B2 (en) * 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
WO2020016656A2 (en) * 2018-07-18 2020-01-23 Glatt Gmbh Extended release formulations of cannabinoids
US11254633B2 (en) 2018-10-05 2022-02-22 Jonas Alcirdas Navickas Cannabis thin layer decarboxylation
WO2020183436A1 (en) * 2019-03-13 2020-09-17 One World Cannabis Ltd. Dosage forms for oral delivery of cannabinoids, method of preparation and uses of same
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
DE102019211195A1 (de) * 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
CN111202767A (zh) * 2019-09-04 2020-05-29 汉义生物科技（北京）有限公司 大麻全草提取物在改善tau蛋白和β-淀粉样蛋白病理损伤中应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2023238122A1 (en) 2022-06-06 2023-12-14 Cannbiorex Pharma Ltd Formulations and oral dosage forms of lipophilic agents
WO2025032115A1 (en) * 2023-08-08 2025-02-13 Avextra Portugal Sa Cannabinoid granule composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361864B9 (en) 2001-02-14 2014-07-09 GW Pharma Limited Liquid spray formulations for buccal delivery of cannabinoids
EP1641437A4 (en) 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
JP2010503663A (ja) * 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー．ブイ． 医薬活性物質を含む顆粒剤とその製造方法
AU2007295179B2 (en) 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078465A (ja) * 2014-10-21 2023-06-06 ブラックモン アーネスト ヴィンソン 大麻抽出物ならびにその調製方法および使用方法
JP2022547409A (ja) * 2019-08-30 2022-11-14 サクソー 充填顆粒、これらの製造方法及びこれらの使用
JP7736671B2 (ja) 2019-08-30 2025-09-09 イーヴィー エスエー 充填顆粒、これらの製造方法及びこれらの使用
JP2023535374A (ja) * 2020-07-17 2023-08-17 カンナ － ケミストリーズ エルエルシー 固体δ９－テトラヒドロカンナビノール（δ９－ｔｈｃ）組成物
JP2023551415A (ja) * 2020-11-16 2023-12-08 インデナ エッセ ピ ア カンナビジオールの固体分散体
JP7360526B1 (ja) 2022-10-21 2023-10-12 第一工業製薬株式会社 組成物
JP7469550B1 (ja) 2022-10-21 2024-04-16 第一工業製薬株式会社 固体組成物及びその製造方法
WO2024085054A1 (ja) * 2022-10-21 2024-04-25 第一工業製薬株式会社 固体組成物及びその製造方法
WO2024085053A1 (ja) * 2022-10-21 2024-04-25 第一工業製薬株式会社 カンナビノイドを含む組成物
JP2024061632A (ja) * 2022-10-21 2024-05-07 第一工業製薬株式会社 固体組成物及びその製造方法
JP2024061198A (ja) * 2022-10-21 2024-05-07 第一工業製薬株式会社 組成物

Also Published As

Publication number Publication date
ES2600465T3 (es) 2017-02-09
AU2013260246B2 (en) 2018-01-25
EP2846768A1 (en) 2015-03-18
AU2013260246A1 (en) 2014-11-27
WO2013169101A1 (en) 2013-11-14
US20160367522A1 (en) 2016-12-22
EP2846768B1 (en) 2016-08-10
CN104363890A (zh) 2015-02-18
US9555019B2 (en) 2017-01-31
CA2872689C (en) 2021-03-30
CN104363890B (zh) 2018-01-26
US20150132400A1 (en) 2015-05-14
AU2013260246A2 (en) 2014-11-27
IN2014DN09718A (enExample) 2015-07-31
CA2872689A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
US9555019B2 (en) Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US12350371B2 (en) Immediate release formulations of cannabinoids
US10245237B2 (en) Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
CA2929325C (en) Compressed tablet containing .delta.9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
EP3171871A1 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
US20180263954A1 (en) Sustained Release Cannabinoid Formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141126

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150107